Cesnicabtagene autoleucel - Gyala Therapeutics
Alternative Names: ARI-0002h; CARTBCMA_J22.9-h:CD8TM:4-1BB:CD3Latest Information Update: 26 Feb 2025
At a glance
- Originator Gyala Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 17 Feb 2025 Gyala Therapeutics plans the phase II GEM-PLASMACAR trial for Plasma cell leukaemia (Newly diagnosed) in Spain (IV, Infusion) in February 2025 (NCT06830733)
- 07 Dec 2024 Pharmacodynamics data from preclinical trials in Multiple myeloma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-2024)
- 13 Jun 2024 Preclinical trials in Multiple myeloma in USA (IV) prior to June 2024